An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site

► A glycan placed on the perimeter of the gp120 CD4bs restricts antibody access. ► Adjuvant Quil A modulates antibody fine specificity. ► Adjuvant Quil A promotes antibody responses to the CD4-binding site. ► The elicited CD4bs antibody titers are too low to achieve significant neutralizing activity.